SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.

Biotech SG&A: Sarepta vs. Arrowhead's Financial Strategies

__timestampArrowhead Pharmaceuticals, Inc.Sarepta Therapeutics, Inc.
Wednesday, January 1, 20142441953649315000
Thursday, January 1, 20153471808975043000
Friday, January 1, 20164099820983749000
Sunday, January 1, 201732022880122682000
Monday, January 1, 201819110051207761000
Tuesday, January 1, 201926556257284812000
Wednesday, January 1, 202052275890317875000
Friday, January 1, 202180981000282660000
Saturday, January 1, 2022124431000451421000
Sunday, January 1, 202390932000481871000
Monday, January 1, 202498761000
Loading chart...

Unleashing the power of data

SG&A Efficiency: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Sarepta Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc. have showcased contrasting strategies in this domain. From 2014 to 2023, Sarepta's SG&A expenses surged by over 870%, peaking in 2023, reflecting its aggressive expansion and investment in administrative capabilities. In contrast, Arrowhead's expenses grew by approximately 300%, indicating a more conservative approach.

Key Insights

  • Sarepta's Strategy: With a peak in 2023, Sarepta's SG&A expenses highlight its commitment to scaling operations, possibly to support its expanding pipeline.
  • Arrowhead's Approach: Despite a significant increase, Arrowhead maintained a steadier growth trajectory, suggesting a focus on cost efficiency.

These trends underscore the diverse strategies biotech firms employ to balance growth and operational efficiency.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025